# US 2009/0275751 A1 · 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275751 A1
- Document ID: US20090275751A1
- Status: Published application
- Kind: A1
- Application number: 12/395,378
- Filed: 2009-02-27
- Published: 2009-11-05
- Earliest claimed: 2000-06-12
- Assignees: Eisai R&D Management Co., Ltd.
- Inventors: Satoshi NAGATO; Kohshi Ueno; Koki Kawano; Yoshihiko Norimine; Koichi Ito; Takaisa Hanada; Masatake Ueno; Hiroyuki Amino; Makoto Ogo; Shinji Hatakeyama; Yoshio Urawa; Hiroyuki Naka; Anthony John Groom; Leanne Rivers; Terrence Smith
- Web page: https://patentgrep.com/patent/US20090275751A1

## CPC

- C07D 213/70: Sulfur atoms
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/64: attached in position 2 or 6
- C07D 213/65: attached in position 3 or 5
- C07D 213/69: Two or more oxygen atoms
- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/76: to which a second hetero atom is attached (nitro radicals C07D213/61)
- C07D 213/81: Amides; Imides
- C07D 213/84: Nitriles
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/06: Peri-condensed systems
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).

## Claims

### Claim 1

A compound represented by the following formula, a salt thereof or hydrates thereof
wherein A1a and A3a are the same as or different from each other and each indicates optionally substituted C6-14 aromatic hydrocarbocyclic group or 5 to 14-membered aromatic heterocyclic group; and R indicates hydrogen atom or a halogen atom.

### Claim 2 (depends on 1)

The compound according to claim 1, a salt thereof or hydrates thereof, wherein A1a and A3a are the same as or different from each other and each represents optionally substituted phenyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, thienyl group, thiazolyl group, furyl group, naphthyl group, quinolyl group, isoquinolyl group, indolyl group, benzimidazolyl group, benzothiazolyl group, benzoxazolyl group, imidazopyridyl group or carbazolyl group.

### Claim 3 (depends on 1)

The compound according to claim 1, a salt thereof or hydrates thereof, wherein A1a and A3a are the same as or different from each other and each represents optionally substituted phenyl group, pyridyl group, pyrimidinyl group, thienyl group or furyl group.

### Claim 4 (depends on 1)

The compound according to claim 1, a salt thereof or hydrates thereof, wherein R is a hydrogen atom or bromine.
